Peptide Profile

Melanotan II // Tanning + Libido

Also known as: Also known as: MT-II · MT2 · Barbie Drug · Pan-Melanocortin Agonist

Broad melanocortin receptor agonist that produces skin darkening (MC1R), increased libido (MC3R/MC4R), and appetite suppression (MC4R) simultaneously. The original 'Barbie drug' — a multi-effect peptide that tans without UV, enhances sexual function, and reduces appetite. Less selective than PT-141 but offers the tanning benefit.

Hormonal & Sexual Subcutaneous Injection Research Compound
MC1-5R
Pan-Agonist
Tan
+ Libido
Multi
Effect
Clinical Development Pipeline
Preclinical
Phase 1
Phase 2
Phase 3
FDA Review
Approved
Quick Reference
Key protocol parameters
Category
Pan-MelanocortinMC1-5R agonist
Route
Subcutaneous
Frequency
Daily during loadingThen maintenance
Half-Life
~33 minutesEffects persist
Dose Range
0.25–0.5mg/dayLoading phase
Cycle
Loading + maintenanceOngoing
Mol. Weight
1024.2 Da
Purity
≥98% HPLCResearch grade
Reconstitution
10mg + 2mL BAC= 5mg/mL

One peptide, five receptor targets.

Melanotan II activates all five melanocortin receptor subtypes with varying affinity. This broad activation profile produces the combined tanning, libido, and appetite effects — but also means more potential side effects than selective compounds like PT-141.

MC1R — Skin Pigmentation
Stimulates melanocytes to produce eumelanin — the dark pigment responsible for tanning. Produces progressive skin darkening over days to weeks, even without UV exposure.
MC3R/MC4R — Sexual Function
The same melanocortin pathway PT-141 targets for libido enhancement. MT-II's sexual effects were the discovery that led to PT-141's development as a standalone sexual health compound.
MC4R — Appetite Suppression
MC4R activation in the hypothalamus reduces appetite and food intake. This anorexigenic effect is a secondary benefit for some users, though it can be excessive at higher doses.

Loading phase, then maintenance.

MT-II uses a loading protocol to build pigmentation, followed by maintenance dosing to sustain it. Start very low — nausea is common and dose-dependent. Tanning effects develop gradually over 1–3 weeks.

Days 1–3 · Micro-Loading
0.1–0.25mg/day SubQ
Start extremely low to assess nausea tolerance. Evening dosing preferred.
Days 4–14 · Loading Phase
0.25–0.5mg/day SubQ
Daily dosing until desired pigmentation. UV exposure amplifies effect.
Weeks 3+ · Maintenance
0.25–0.5mg 1–2x/week
Reduce to maintenance once desired tan is achieved.
Ongoing · Sustain
As needed
Increase frequency before sun exposure seasons.
⚠ Important: Melanotan II is a research compound and not FDA-approved. It carries risks including mole changes and potential melanoma concern. Dermatological screening before use is strongly recommended. This is educational content — not medical advice.

The University of Arizona origin story.

Melanotan II was developed at the University of Arizona in the 1990s by researchers seeking a tanning agent that could protect fair-skinned individuals from UV radiation and skin cancer. The unexpected sexual arousal side effects were significant enough to spawn an entire research program.

The compound activates all five melanocortin receptor subtypes (MC1R–MC5R), explaining its multi-effect profile. The tanning effect (MC1R) was the intended target; the sexual enhancement (MC3R/MC4R) and appetite suppression (MC4R) were serendipitous discoveries.

Safety concerns center on the potential for melanocyte overstimulation — existing moles can darken, new moles can appear, and there is a theoretical (unproven but concerning) link to melanoma acceleration. Dermatological screening before and during use is the standard recommendation.

Melanocortin agonist comparison.

CompoundSelectivityTanningLibidoAppetite
Melanotan IIPan-MC (1-5R)✓ Strong✓ Strong↓ Suppressed
PT-141MC3R/MC4R✗ None✓ StrongMinimal
Melanotan I (Afamelanotide)MC1R Selective✓ Strong✗ Minimal✗ None

What to watch for.

Melanotan II's side effect profile is manageable with proper protocol adherence. Baseline blood work before starting and periodic monitoring during use is essential.

Side Effects
  • Nausea (very common — dose-dependent, improves with time)
  • Facial flushing (vasodilation — common)
  • Mole darkening and new mole formation (monitor carefully)
  • Fatigue/drowsiness (common, dose during evening)
  • Appetite suppression (can be excessive)
  • Spontaneous erections in men (dose-dependent)
  • Theoretical melanoma concern (unproven but warrants screening)
  • Injection site reactions
Blood Work Panel
  • Full dermatological screening (mole mapping baseline)
  • Blood pressure monitoring
  • Comprehensive metabolic panel
  • Hormone panel (baseline)
  • Follow-up mole checks every 3–6 months during use
Stacking Notes
  • Do NOT combine with PT-141 (overlapping melanocortin activity)
  • UV exposure amplifies tanning effect — use cautiously
  • Dermatological screening mandatory before starting
  • BPC-157 for nausea management during loading
  • Lower dose reduces side effects — start at 0.1mg
  • Some users prefer PT-141 for libido without tanning side effects
Storage & Handling
  • Lyophilized: refrigerate at 2–8°C (36–46°F)
  • Reconstituted: refrigerate, use within 28 days
  • Protect from light (especially important for MT-II)
  • Do not freeze reconstituted solution
  • Insulin syringes for precise low-dose measurement
Agent Verdict

The original multi-tool — powerful but imprecise.

Melanotan II does three things at once: tans your skin, enhances libido, and suppresses appetite. For some users, that's the perfect profile. For others, PT-141 (libido only) or Melanotan I (tanning only) offer cleaner, more targeted alternatives. The main safety concern is melanocyte overstimulation — mole darkening, new mole formation, and the theoretical melanoma risk. Dermatological screening before starting is non-negotiable. Start at 0.1mg to manage nausea, dose in the evening, and monitor your skin closely. If you just want the libido effect without tanning, use PT-141 instead.

Go Deeper
Melanotan II protocol.

Our free Protocol Guide includes the complete hormonal section — MT-II loading protocol, PT-141 comparison, and safety monitoring.

43 peptide profiles
7 protocol templates
Blood work ranges
Free forever
Free Protocol Guide V3
260 peptides · 185 stacks · 12 protocol categories · blood work templates
260
Profiles
185
Stacks
12
Categories
Free Instant Access
Unlock your protocols.
Research-backed peptide guides, dosing calculators, and weekly intel — used by biohackers worldwide.
Protocol Guide V3 PDF
260 peptide profiles, 185 stack combinations, 12 protocol categories
The Protocol Brief Weekly
Weekly research breakdowns, protocol spotlights, blood work insights
Select at least one option
Enter your first name
Enter a valid email

You're in.

No spam, ever. Unsubscribe anytime.